Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 1/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.33 |
| ▸ | GAA | P10253 | 1/20 | 0.33 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.33 |
| ▸ | NPC1 | O15118 | 1/20 | 0.30 |
| ▸ | TP53 | P04637 | 1/20 | 0.30 |
| ▸ | HPGD | P15428 | 1/20 | 0.30 |
| ▸ | RAB9A | P51151 | 1/20 | 0.30 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.30 |
| ▸ | LMNA | P02545 | 1/20 | 0.30 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12278962 | 0.94 | THRA (0.35) | MEN1ALDH1A1GAAKMT2ATP53 | |
| SCHEMBL12320830 | 0.71 | RAB9A (0.33) | HPGDRAB9A | |
| SCHEMBL3871715 | 0.69 | ALDH1A1 (0.35) | MEN1ALDH1A1GAAKMT2ANPC1 | |
| SCHEMBL28139720 | 0.69 | SKP2 (0.37) | MEN1ALDH1A1GAAKMT2ANPC1 | |
| SCHEMBL28318893 | 0.69 | ALDH1A1 (0.38) | MEN1ALDH1A1GAAKMT2ANPC1 | |
| SCHEMBL7010771 | 0.67 | — | — | |
| SCHEMBL28236195 | 0.67 | TSHR (0.38) | MEN1ALDH1A1GAAKMT2AHPGD | |
| SCHEMBL7005459 | 0.67 | — | — | |
| SCHEMBL29288295 | 0.67 | PTGS2 (0.38) | ALDH1A1TP53LMNA | |
| SCHEMBL15074364 | 0.66 | LPL (0.39) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3407877-B1 | NLRP3 INHIBITORS FOR THE TREATMENT OF INFLAMMATORY SKIN DISORDERS | GALDERMA RES & DEV (FR) | 2020-03-04 | — | — | EP | disclosed |